Premium
Quinoline Glycoconjugates as Potentially Anticancer and Anti‐Inflammatory Agents: An Investigation Involving Synthesis, Biological Screening, and Docking
Author(s) -
Pallavi Badvel,
Sharma Prachi,
Baig Noorullah,
Kumar Madduluri Vimal,
Sah Ajay K.,
Saumya Udit,
Dubey Uma S.,
Shukla Paritosh
Publication year - 2020
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.202002345
Subject(s) - glycoconjugate , hela , quinoline , docking (animal) , chemistry , in vitro , anti inflammatory , potency , enzyme , pharmacology , drug , drug discovery , biochemistry , combinatorial chemistry , stereochemistry , biology , medicine , organic chemistry , nursing
The present work is a preliminary report of synthesis of a series of targeted 4,6‐ O ‐ethylidene‐ β ‐D‐glucopyranosylamine glycoconjugate quinoline 4‐carboxylic acid derivatives followed by a quick evaluation of their anti‐inflammatory and anticancer activities. Compounds C5 and C8 exhibited highest anti‐inflammatory activity against human COX‐2 enzyme. Anticancer studies were also performed in vitro which revealed C8 as a promising candidate against HeLa, human cervical cancer cell lines. The anti‐inflammatory and anticancer activity was further confirmed by molecular docking studies for all the synthesized molecules. That all the compounds showed potency, seems to validate our initial hypothesis concerning a positive correlation between anticancer and anti‐inflammatory activity for the designed quinoline glycoconjugates.